Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

A 5354Session 2025-2026

Requires health insurers to provide coverage without cost-sharing for opioid antagonists and devices

A5354

Underlined text would be added to current law. Struck-through text would be removed.

Skip to main content

New York State Assembly

Speaker Carl E. Heastie

  • Assembly Members
  • Legislative Info
  • Public Hearings
  • Speaker's Press
  • Assembly Reports
  • Committees & More
  • Bill Search Home
  • Laws
  • Legislative Calendar
  • Public Hearing Schedule
  • Assembly Calendars
  • Assembly Committee Agenda
Javascript must be enabled to properly view this page. Bill No.:  
     
  •  Summary 
  •  
  •  Actions 
  •  
  •  Committee&nbspVotes 
  •  
  •  Floor&nbspVotes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber&nbspVideo/Transcript 

A05354 Summary:

BILL NOA05354
 
SAME ASNo Same As
 
SPONSORSteck
 
COSPNSR
 
MLTSPNSR
 
Amd ??3216, 3221 & 4303, Ins L
 
Requires health insurers to provide coverage without cost-sharing for opioid antagonists and devices; provides that no prior authorization of premedical review for coverage of such opioid antagonist is required.
Go to top

A05354 Text:

STATE OF NEW YORK ________________________________________________________________________ 5354 2025-2026 Regular Sessions IN ASSEMBLY February 13, 2025 ___________ Introduced by M. of A. STECK -- read once and referred to the Committee on Insurance AN ACT to amend the insurance law, in relation to requiring health insurers to provide coverage without cost-sharing for opioid antag- onists and devices The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subsection (i) of section 3216 of the insurance law is 2 amended by adding a new paragraph 40 to read as follows: 3 (40) (A) (i) Every policy which provides coverage for prescription 4 drugs shall include coverage for at least one opioid antagonist and 5 device. No prior authorization or premedical review for coverage of an 6 opioid antagonist is required. 7 (ii) As used in this paragraph "opioid antagonist and device" means a 8 drug approved by the food and drug administration that, when adminis- 9 tered, negates or neutralizes in whole or in part the pharmacological 10 effects of an opioid in the body. "Opioid antagonist" shall be limited 11 to medications approved by the department of health for such purpose. 12 (B) The coverage mandated by this paragraph shall include opioid 13 antagonists prescribed or dispensed via standing order or collaborative 14 practice agreement intended for use on patients other than the insured. 15 (C) A policy shall not impose a deductible, co-insurance, co-payment, 16 or any other cost-sharing requirement on such coverage provided pursuant 17 to this paragraph. 18 § 2. Subsection (l) of section 3221 of the insurance law is amended by 19 adding a new paragraph 7-c to read as follows: 20 (7-c) (A) (i) Every policy which provides coverage for prescription 21 drugs shall include coverage for at least one opioid antagonist and 22 device. No prior authorization or premedical review for coverage of an 23 opioid antagonist is required. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD07388-02-5 A. 5354 2 1 (ii) As used in this paragraph "opioid antagonist and device" means a 2 drug approved by the food and drug administration that, when adminis- 3 tered, negates or neutralizes in whole or in part the pharmacological 4 effects of an opioid in the body. "Opioid antagonist" shall be limited 5 to medications approved by the department of health for such purpose. 6 (B) The coverage mandated by this paragraph shall include opioid 7 antagonists prescribed or dispensed via standing order or collaborative 8 practice agreement intended for use on patients other than the insured. 9 (C) A group or blanket policy subject to this paragraph shall not 10 impose a deductible, co-insurance, co-payment, or any other cost-sharing 11 requirement on such coverage provided pursuant to this paragraph. 12 § 3. Section 4303 of the insurance law is amended by adding a new 13 subsection (ww) to read as follows: 14 (ww) (1) (A) Every policy that is issued, amended, renewed, effective, 15 or delivered on or after January first, two thousand twenty-six and 16 provides coverage for prescription drugs shall include coverage for at 17 least one opioid antagonist and device. No prior authorization or 18 premedical review for coverage of an opioid antagonist is required. 19 (B) As used in this subsection "opioid antagonist and device" means a 20 drug approved by the food and drug administration that, when adminis- 21 tered, negates or neutralizes in whole or in part the pharmacological 22 effects of an opioid in the body. "Opioid antagonist" shall be limited 23 to medications approved by the department of health for such purpose. 24 (2) A contract subject to this subsection shall not impose a deduct- 25 ible, coinsurance, copayment, or any other cost-sharing requirement on 26 such coverage provided pursuant to this subsection. 27 § 4. This act shall take effect immediately and shall apply to poli- 28 cies and contracts issued, renewed, modified, altered or amended on or 29 after such effective date. Go to top <link href="/styles/noscript_styles.css" rel="stylesheet"/> Sitemap Request Information Directions and Maps

Official text from the New York Legislature. Formatting has been adapted for reading on Ratifi.